Herpes Simplex Virus (HSV) Vaccines Market Expected to Witness a Sustainable Expansion by 2025 | Leading Company’s - Sanofi, GSK, Genocea Biosciences, Vical

Overview of Global Herpes Simplex Virus (HSV) Vaccines Market:

This report provides in-depth study of “Global Herpes Simplex Virus (HSV) Vaccines Market 2020” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Herpes Simplex Virus (HSV) Vaccines Market report also provides an in-depth survey of key players in the market organization.

Major key factors driving the growth of the Global Herpes Simplex Virus (HSV) Vaccines Market are extensive research and development, increasing prevalence of HSV infection, rise in rate of new infections, and continuous mutations in the microorganisms leading to new strains. In addition, increase in modes of transmission of the infectious disease and lack of cleanliness in developing regions has propelled the Global Herpes Simplex Virus (HSV) Vaccines Market. As per the World Health Organization (WHO), more women are infected with HSV-2 than men. In 2012, an estimated 267 million women and 150 million men were living with the infection.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/267948 .

Firstly, the report provides a basic overview of the Market including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major Market players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2020-2025 market shares for each company.

According to the regional analysis, Prevalence of herpes simplex virus infection is higher in APAC and Middle East & Africa than in North America and Europe. As per the statistics published by World Health Organization in 2012, an estimated 3.7 billion people under the age of 50, or 67% of the population, had HSV-1 infection globally. Estimated prevalence of the infection was the highest in countries in Africa (87%) and lowest in the Americas (40% to 50%).

In the end, the report makes some important proposals for a new project of Herpes Simplex Virus (HSV) Vaccines Market before evaluating its feasibility. Overall, the report provides an in-depth insight of 2013-2025 global Herpes Simplex Virus (HSV) Vaccines market covering all important parameters.

Global Key Vendors:

1 Sanofi

2 GlaxoSmithKline

3 Genocea Biosciences

4 Vical and More……………….

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Herpes Simplex Virus (HSV) Vaccines Market Report 2020” @ https://www.businessindustryreports.com/buy-now/267948/single .

Product Type Segmentation

1 GEN-003

2 VCL-HB01

3 HSV529

Industry Segmentation

1 HSV-1 (Oral Herpes)

2 HSV-2 (Genital Herpes)

Top Medical Industry News:

Sanofi (May 22, 2020) - Dupixent (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints - Sanofi and Regeneron Pharmaceuticals, Inc. today announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). The trial met both of its co-primary endpoints, as well as all key secondary endpoints. Dupixent is the first and only biologic to show positive and clinically-meaningful results in this population as part of a Phase 3 trial. An on-going Part B portion of the Phase 3 trial evaluates an additional Dupixent dosing regimen.

EoE is a chronic and progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly, leading to difficulties swallowing. If untreated, symptoms and inflammation can progress, causing functional damage and scarring of the esophagus. EoE can lead to esophageal food impaction, requiring immediate emergency room visits. Almost half of the patients in this trial had prior procedures such as dilation of their esophagus, and almost three-quarters had previously been treated with corticosteroids. In the U.S., there are approximately 160,000 patients with EoE who are currently treated, of which an estimated 50,000 have failed multiple treatments. There are currently no therapies approved by the U.S. Food and Drug Administration (FDA).

“Eosinophilic esophagitis can be debilitating, and there are no approved treatment options. It impacts patients’ ability to eat, causes severe pain and often results in repeated emergency room visits and medical procedures,” said George D. Yancopoulos, M.D., Ph.D., Co-Founder, President and Chief Scientific Officer of Regeneron. “These data are particularly impressive as Dupixent not only dramatically reduced eosinophils in the esophagus, but also improved all clinical, anatomic and histologic measures of the disease. In the past, EoE was thought to be a disease caused by eosinophils, but other biologics that decrease the eosinophils in the esophagus did not demonstrate consistent clinical or anatomical improvements. These Dupixent results demonstrate EoE is caused by multiple aspects of type 2 inflammation, driven by interleukin-4 and interleukin-13. EoE is the fourth atopic or type 2 inflammatory disease in which Dupixent has pivotal data demonstrating significant efficacy.”'

“These data demonstrate Dupixent’s potential to continue to address treatment gaps across the spectrum of type 2 inflammatory diseases as common as asthma and as rare as eosinophilic esophagitis,” said John Reed, M.D, Ph.D, Global Head of Research and Development at Sanofi. “For the first time in a Phase 3 trial, patients reported an improvement in their ability to swallow food. For patients with eosinophilic esophagitis who are living with restricted diets and, in some cases, repeated hospital interventions, these findings are encouraging.”

Part A of the trial enrolled 81 patients (42 with Dupixent, 39 with placebo) aged 12 years and older with EoE, as determined by histological and patient-reported measures. The co-primary endpoints assessed the change from baseline in the Dysphagia Symptom Questionnaire (DSQ), a patient-reported measure of difficulty swallowing, and the proportion of patients achieving peak esophageal intraepithelial eosinophil count of ≤6 eos/hpf, a measure of an esophageal inflammation, at 24 weeks.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/267948 .

Major Points in Table of Contents:

Global Herpes Simplex Virus (HSV) Vaccines Market Report 2020

1 Herpes Simplex Virus (HSV) Vaccines Product Definition

2 Global Herpes Simplex Virus (HSV) Vaccines Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Herpes Simplex Virus (HSV) Vaccines Shipments

2.2 Global Manufacturer Herpes Simplex Virus (HSV) Vaccines Business Revenue

2.3 Global Herpes Simplex Virus (HSV) Vaccines Market Overview

2.4 COVID-19 Impact on Herpes Simplex Virus (HSV) Vaccines Industry

3 Manufacturer Herpes Simplex Virus (HSV) Vaccines Business Introduction

3.1 Sanofi Herpes Simplex Virus (HSV) Vaccines Business Introduction

3.2 GlaxoSmithKline Herpes Simplex Virus (HSV) Vaccines Business Introduction

3.3 Genocea Biosciences Herpes Simplex Virus (HSV) Vaccines Business Introduction

3.4 Vical Herpes Simplex Virus (HSV) Vaccines Business Introduction

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.